Status:
UNKNOWN
Role of CEUS as a Secondary Diagnostic Modality
Lead Sponsor:
Seoul National University Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To determine the role of contrast-enhanced ultrasound (CEUS) as a second-line imaging modality after gadoxetate-enhanced MRI (Gd-EOB-MRI) for identifying hepatocellular carcinoma (HCC) among at-risks ...
Detailed Description
The purpose of our study was to evaluate the diagnostic ability of CEUS with perflubutane to identify HCC on the indeterminate observation in Gd-EOB-MRI and to establish the role of CEUS as a second-l...
Eligibility Criteria
Inclusion
- at risk of HCC by Liver Imaging Reporting and Data System (LI-RADS)
- at least one treatment-naïve solid hepatic observation (≥1 cm) while surveillance using US, CT or MRI
- signed informed consent
Exclusion
- congestive hepatopathies
- severe cardiovascular dysfunction
- no recent cross-sectional images within 4 weeks
- suboptimal cross-sectional images quality
Key Trial Info
Start Date :
June 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04494022
Start Date
June 8 2020
End Date
December 31 2021
Last Update
July 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea